Treatment of melanoma brain metastases: A new paradigm

Cancer Journal

Volumn 18, Issue 2, 2012, Pages 208-212

  Carlino, Matteo S ^a,b   Fogarty, Gerald B ^c,d   Long, Georgina V ^b,c  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

^d Genesis Cancer Care Pty Ltd   (Australia)

Author keywords

BRAF inhibitors; BRAF mutant; brain metastases; dabrafenib; GSK2118436; ipilimumab; Metastatic melanoma; stage IV melanoma; stereotactic radiosurgery; vemurafenib; whole brain radiotherapy

Indexed keywords

CORTICOSTEROID; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; IPILIMUMAB; TEMOZOLOMIDE; VEMURAFENIB;

ADOPTIVE IMMUNOTHERAPY; BLEEDING; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CAPILLARY LEAK SYNDROME; CHEMORADIOTHERAPY; EDEMA; HUMAN; INTRACRANIAL PRESSURE; MELANOMA; MORBIDITY; OVERALL SURVIVAL; PATIENT SELECTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STEREOTACTIC RADIOSURGERY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

BRAIN NEOPLASMS; HUMANS; MELANOMA; PROGNOSIS; TREATMENT OUTCOME;

EID: 84859447241     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31824b2890     Document Type: Review

References (57)

1. Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev. 2004;30:515-520. (Pubitemid 39157852)
2. Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117:1687-1696.
3. Carlino MS, Atkins MB, Warneke CL, et al. Differences between Australia (OZ) and the United States (US) in the Patterns, Prognosis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study. Pigment Cell Melanoma Res. 2010;23:946.
4. Amer MH, Al-Sarraf M, Baker LH, et al. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42:660-668. (Pubitemid 8405861)
5. de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983; 43:3427-3433. (Pubitemid 13061609)
6. Stevens G, Firth I, Coates A. Cerebral metastases from malignant melanoma. Radiother Oncol. 1992;23:185-191.
7. Fife KM. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22:1293-1300. (Pubitemid 41079844)
8. Staudt M, Lasithiotakis K, Leiter U, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer. 2010;102:1213-1218.
9. Zakrzewski J, Geraghty LN, Rose AE, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117: 1711-1720.
10. Sampson JH, Carter JH Jr, Friedman AH, et al. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88:11-20. (Pubitemid 28018958)
11. Eigentler TK, Figl A, Krex D, et al. Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer. 2011; 117:1697-1703.
12. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19:3622-3634. (Pubitemid 32786275)
13. Jakob JA, Bassett RL, Ng CS, et al. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. J Clin Oncol. 2011;29[suppl]: Abstract 8500.
14. Zacest AC, Besser M, Stevens G, et al. Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. J Neurosurg. 2002;96:552-558. (Pubitemid 34230211)
15. Gupta G, Robertson AG, MacKie RM. Cerebral metastases of cutaneous melanoma. Br J Cancer. 1997;76:256-259. (Pubitemid 27279668)
16. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37: 745-751. (Pubitemid 27181303)
17. Morris SL, Low SH, A'Hern RP, et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer. 2004;91:829-833. (Pubitemid 39273770)
18. Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96: 103-114.
19. Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:97-102.
20. Raizer JJ, Hwu WJ, Panageas KS, et al. Brain and leptomeningeal me-tastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol. 2008;10:199-207.
21. Suh JH. Stereotactic radiosurgery for the management of brain metast-ases. N Engl J Med. 2010;362:1119-1127.
22. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322:494-500. (Pubitemid 20067825)
23. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33:583-590. (Pubitemid 23161878)
24. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78:1470-1476. (Pubitemid 26317868)
25. Bindal RK, Sawaya R, Leavens ME, et al. Surgical treatment of multiple brain metastases. J Neurosurg. 1993;79:210-216. (Pubitemid 23215837)
26. Muacevic A, Wowra B, Siefert A, et al. Microsurgery plus whole brain irradiation versus gamma knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neurooncol. 2007;87:299-307.
27. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665-1672. (Pubitemid 38670323)
28. Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45: 427-434. (Pubitemid 29408559)
29. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 1971; 31:830-833.
30. Dossgg LL, Memula N. The radioresponsiveness of melanoma. Int J Radiat Oncol Biol Phys. 1982;8:1131-1134. (Pubitemid 12053187)
31. Liew DN, Kano H, Kondziolka D, et al. Outcome predictors of gamma knife surgery for melanoma brain metastases. Clinical article. J Neurosurg. 2011;114:769-779.
32. Khuntia D, Brown P, Li J, et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24:1295-1304. (Pubitemid 46622033)
33. Carella RJ, Gelber R, Hendrickson F, et al. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer. 1980;45:679-683. (Pubitemid 10174607)
34. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485-1489. (Pubitemid 28507400)
35. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483-2491. (Pubitemid 43854963)
36. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134-141.
37. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009; 10:1037-1044.
38. Fogarty G, Morton R, Vardy J, et al. Whole brain radiotherapy after local treatment of brain metastases in melanoma patientsVa randomised phase III trial. BMC Cancer. 2011;11:142.
39. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
40. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364:2517-2526.
41. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
42. Meulemans A, Giroux B, Hannoun P, et al. Permeability of two nitro-soureas, carmustine and fotemustine in rat cortex. Chemotherapy. 1989; 35:313-319. (Pubitemid 19235952)
43. Stupp R, Ostermann S, Leyvraz S, et al. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration. Proc Am Soc Clin Oncol. 2001;20: Abstract 232.
44. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French mul-ticenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:1873-1878. (Pubitemid 20385954)
45. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacar-bazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118-1125. (Pubitemid 41095046)
46. Agarwala SS. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004; 22:2101-2107. (Pubitemid 41095143)
47. Mornex F, Thomas L, Mohr P, et al. A prospective randomized multi-centre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res. 2003;13:97-103. (Pubitemid 36269821)
48. Margolin, Atkins, Thompson, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002;128:214-218.
49. Hofmann M, Kiecker F, Wurm R, et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neuro-oncol. 2006;76:59-64. (Pubitemid 43115761)
50. Lawrence DP, Hamid O, McDermott DF, et al. Phase II trial of ipilim-umab monotherapy in melanoma patients with brain metastases. J Clin Oncol. 2010;28: Abstract 8523.
51. Lebbé C, McDermott D, Robert C, et al. Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analysis from a phase III trial. Ann Oncol. 2010; Abstract 13240.
52. Guirguis LM, Yang JC, White DE, et al. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother. 2002;25:82-87. (Pubitemid 34052838)
53. Majer M, Jensen RL, Shrieve DC, et al. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metas-tases. Cancer. 2007;110:1329-1337. (Pubitemid 47435606)
54. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative che-moradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.
55. Hong JJ, Rosenberg SA, Dudley ME, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res. 2010;16:4892-4898.
56. Long GV, Kefford RF, Carr PJA, et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (Mets). Ann Oncol. 2010: Abstract LBA 27.
57. Dummer R, Rinderknecht J, Goldinger SM, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol. 2011;29[suppl]: Abstract 8548.